U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C8H10N6.H2O4S
Molecular Weight 288.284
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of DIHYDRALAZINE SULFATE

SMILES

OS(O)(=O)=O.NNC1=C2C=CC=CC2=C(NN)N=N1

InChI

InChIKey=BWHAMWGGORIDBK-UHFFFAOYSA-N
InChI=1S/C8H10N6.H2O4S/c9-11-7-5-3-1-2-4-6(5)8(12-10)14-13-7;1-5(2,3)4/h1-4H,9-10H2,(H,11,13)(H,12,14);(H2,1,2,3,4)

HIDE SMILES / InChI

Description

Dihydralazine is a compound with antihypertensive properties and is in clinical trials, where is studied its effect on kidney function and hormones in healthy individuals.

Approval Year

Unknown
139594
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Not Provided
504
Unknown

Approved Use

Unknown
PubMed

PubMed

TitleDatePubMed
Influence of metabolic activation on the induction of micronuclei by antihypertensive drugs in L929 cells.
2001 Feb
[Effect of Urapidil in antihypertensive therapy of preeclampsia on newborns].
2001 Sep
Aldehyde-sequestering drugs: tools for studying protein damage by lipid peroxidation products.
2002 Dec 27
The impact of maternal plasma volume expansion and antihypertensive treatment with intravenous dihydralazine on fetal and maternal hemodynamics during pre-eclampsia: a clinical, echo-Doppler and viscometric study.
2004 Apr
3,6-Bis(2-pyridyl)di-1,2,4-triazolo[3,4-a:4',3'-c]phthalazine.
2004 Sep
Positive effects of nitric oxide on left ventricular function in humans.
2006 Jul
[Hypertension in pregnancy].
2006 Mar
Progress curve analysis of CYP1A2 inhibition: a more informative approach to the assessment of mechanism-based inactivation?
2007 Dec
Method development for dihydralazine with HPLC-MS/MS--an old but tricky substance in human plasma.
2007 Jan 17
Emitting species in chemiluminescence reactions with acidic potassium permanganate: a re-evaluation based on new spectroscopic evidence.
2009 Sep
A correlation between the in vitro drug toxicity of drugs to cell lines that express human P450s and their propensity to cause liver injury in humans.
2014 Jan
Patents

Patents

04152435
9

Sample Use Guides

In Vivo Use Guide
The influence of a pure afterload reduction on systolic time intervals and various echocardiographic indices was assessed in six healthy volunteers, who underwent a single blind placebo controlled trial of three regimens of intravenous dihydralazine (6.25, 12.5, and 25.0 mg).
Route of Administration: Intravenous
In Vitro Use Guide
Curator's Comment: In mice bone marrow cells, dihydralazine induced a modest but statistically significant increase over controls in the frequency of sister chromatid exchanges, the rank of potencies being in this case dihydralazine greater than endralazine greater than hydralazine. In the Ames reversion test all three drugs behaved as direct-acting mutagens of low potency, whose activity was not influenced by rat liver nor by mouse liver or lung S-9 fractions. Hydralazine and dihydralazine elicited mixed genetic mechanisms of mutations, while endralazine exclusively induced frameshift errors in Salmonella DNA.
Unknown
Name Type Language
DIHYDRALAZINE SULFATE
MART.   WHO-DD  
Common Name English
DIHYDRALAZINE SULPHATE
Common Name English
DIHYDRALAZINE SULFATE [MI]
Common Name English
DIHYDRALAZINE SULFATE [MART.]
Common Name English
Dihydralazine sulfate [WHO-DD]
Common Name English
1,4-DIHYDRAZINOPHTHALAZINE HYDROGEN SULFATE
Systematic Name English
1,4-DIHYDRAZINOPHTHALAZINE HYDROGEN SULPHATE
Systematic Name English
Code System Code Type Description
EVMPD
SUB130439
Created by admin on Fri Dec 15 14:57:40 GMT 2023 , Edited by admin on Fri Dec 15 14:57:40 GMT 2023
ALTERNATIVE
RXCUI
235959
Created by admin on Fri Dec 15 14:57:40 GMT 2023 , Edited by admin on Fri Dec 15 14:57:40 GMT 2023
PRIMARY RxNorm
MERCK INDEX
m4457
Created by admin on Fri Dec 15 14:57:40 GMT 2023 , Edited by admin on Fri Dec 15 14:57:40 GMT 2023
PRIMARY Merck Index
ChEMBL
CHEMBL35505
Created by admin on Fri Dec 15 14:57:40 GMT 2023 , Edited by admin on Fri Dec 15 14:57:40 GMT 2023
PRIMARY
FDA UNII
1C2B1W91NK
Created by admin on Fri Dec 15 14:57:40 GMT 2023 , Edited by admin on Fri Dec 15 14:57:40 GMT 2023
PRIMARY
EVMPD
SUB01702MIG
Created by admin on Fri Dec 15 14:57:40 GMT 2023 , Edited by admin on Fri Dec 15 14:57:40 GMT 2023
PRIMARY
EPA CompTox
DTXSID10223501
Created by admin on Fri Dec 15 14:57:40 GMT 2023 , Edited by admin on Fri Dec 15 14:57:40 GMT 2023
PRIMARY
SMS_ID
100000092770
Created by admin on Fri Dec 15 14:57:40 GMT 2023 , Edited by admin on Fri Dec 15 14:57:40 GMT 2023
PRIMARY
PUBCHEM
81764
Created by admin on Fri Dec 15 14:57:40 GMT 2023 , Edited by admin on Fri Dec 15 14:57:40 GMT 2023
PRIMARY
DRUG BANK
DBSALT002931
Created by admin on Fri Dec 15 14:57:40 GMT 2023 , Edited by admin on Fri Dec 15 14:57:40 GMT 2023
PRIMARY
CAS
7327-87-9
Created by admin on Fri Dec 15 14:57:40 GMT 2023 , Edited by admin on Fri Dec 15 14:57:40 GMT 2023
PRIMARY
NCI_THESAURUS
C81520
Created by admin on Fri Dec 15 14:57:40 GMT 2023 , Edited by admin on Fri Dec 15 14:57:40 GMT 2023
PRIMARY
ECHA (EC/EINECS)
230-808-0
Created by admin on Fri Dec 15 14:57:40 GMT 2023 , Edited by admin on Fri Dec 15 14:57:40 GMT 2023
PRIMARY
ACTIVE MOIETY
Structure of DIHYDRALAZINE
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966